Formed in 2009, the Buffalo Translational Consortium (BTC) includes the leading academic, health care and research institutions in the Buffalo region, along with key community partners. Each BTC institution is represented in the governance of UB's Clinical and Translational Science Institute.
The University at Buffalo Clinical and Translational Science Institute (CTSI) serves as the hub for the entire Buffalo Translational Consortium (BTC). The BTC is a regional collaboration of the University at Buffalo health sciences schools, leading clinical institutions (UB|MD Practice Plan, Kaleida Health, Roswell Park Comprehensive Cancer Center, Erie County Medical Center and the Buffalo VA Medical Center), research institutes and community organizations. All partners share a commitment to perform research with a vision to improve health and reduce health disparities in our community.
With an innovative, collaborative, inclusive culture, we support the advancement of research across the entire translational spectrum – from translating basic science discoveries into health care interventions to clinical trials to bringing these advances into real-world community settings. We train and mentor the next generation of clinical and translational scientists and train future physicians, nurses and other health care professionals in using the newest advances in research. We engage the community and health care providers in all phases of clinical research – driving the research agenda, working as part of research teams, participating in clinical trials and benefiting from research results. The work of the Buffalo Translational Consortium has a transformative impact on the health our community.
Buffalo's CTSI is one of more than 50 medical research institutions nationally that receive Clinical and Translational Science Awards (CTSA) Program funding through the National Institutes of Health (NIH). We partner with our counterparts in the national CTSA consortium to advance the goals of clinical and translational research with the ultimate goal of bringing more evidence-based treatments to more patients more quickly.